Literature DB >> 29430118

Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.

Koramadai Karuppusamy Kamaleshwaran1, Barani Kumar Pollachi Balasundararaj2, Raghi Jose1, Ajit Sugunan Shinto1.   

Abstract

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (Ga-68 PSMA PET/CT) is a promising diagnostic tool for patients with prostate cancer. Penile metastasis from prostate cancer is a rare phenomenon that infrequently manifests as malignant priapism. We present a case of 79-year-old patient diagnosed as a case of adenocarcinoma prostate presenting with penile metastases imaged using Ga-68 PSMA PET/CT.

Entities:  

Keywords:  Gallium-68 prostate-specific membrane antigen positron emission tomography/computer tomography; penile metastasis; priapism; prostate cancer

Year:  2018        PMID: 29430118      PMCID: PMC5798101          DOI: 10.4103/ijnm.IJNM_107_17

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


Introduction

Gallium-68 prostate-specific membrane antigen positron emission tomography/computer tomography (Ga-68 PSMA PET/CT) is the best available imaging tool in the evaluation of prostate cancer.[1] The penis is an uncommon site for metastasis originating from a prostate cancer. A review of the literature on penile metastases returned approximately 400 published cases, with priapism being the initial presentation in 20%–50% of cases.[2] Our case describes the image findings of Ga-68 PSMA PET/CT in an unusual case of prostate cancer with penile metastasis presenting with priapism.

Case Report

A 79-year-old male presented with a complaint of painful urinary outflow obstruction and persistent erection. Biopsy of prostate gland revealed carcinoma prostate (poorly differentiated adenocarcinoma, Gleason's score 3 + 4, initial prostate-specific antigen (PSA) >100 ng/ml). He was referred for the whole body Ga-68 PSMA PET/CT [Figure 1] for staging which showed an enhancing lesion in the prostate gland (with a maximum standardized uptake value [SUVmax] of 16) and thickening of entire shaft of penis with intense PSMA uptake (SUVmax of 35) [Figure 2]. He underwent bilateral orchidectomy and radiotherapy and is on follow-up.
Figure 1

Whole body Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography maximum projection image shows uptake in primary prostate lesion and penile metastasis

Figure 2

Sagittal computer tomography (a), positron emission tomography (b), positron emission tomography/computed tomography (c), maximum projection image (d), Gallium-68 prostate-specific membrane antigen positron emission tomography/computer tomography showing soft-tissue enhancing lesion in the prostate gland and corpora cavernosa thickening of penis with intense prostate-specific membrane antigen uptake suggesting metastasis

Whole body Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography maximum projection image shows uptake in primary prostate lesion and penile metastasis Sagittal computer tomography (a), positron emission tomography (b), positron emission tomography/computed tomography (c), maximum projection image (d), Gallium-68 prostate-specific membrane antigen positron emission tomography/computer tomography showing soft-tissue enhancing lesion in the prostate gland and corpora cavernosa thickening of penis with intense prostate-specific membrane antigen uptake suggesting metastasis

Discussion

Secondary penile lesions are a rare phenomenon, first described in 1870 by Eberth. Reviews of published case reports reveal that organs along the genitourinary tract, such as the prostate and bladder, are the most common primary sites. Of the 394 documented cases, 129 (33%) cases were of prostate origin, and bladder cancer was a close second with 118 published cases (30%).[2] Clinical manifestations of penile metastases include penile masses or nodules, ulceration, obstructive or irritative urinary symptoms, hematuria, and malignant priapism in 20%–50% of the documented cases.[3] Different mechanisms of persistent erection due to malignancy have been described, with a distinction between low-flow and high-flow priapism. Most incidences of malignant priapism are considered to be low-flow priapisms and are believed to be due to neoplastic invasions into the cavernous sinuses and venous system, causing a complete blockage, and a consequent unrelenting erection. The penile shaft is the most common anatomical site to be affected in case of a penile metastasis. Metastatic spread of prostate cancer to the penis occurs by several routes. Retrograde venous or direct lymphatic/vascular invasion and direct extension through the lumen of vas deferens are the most common mechanisms.[4] PSMA is a transmembrane protein that has considerable over expression on most prostate cancer cells. The whole body Ga-68 PSMA PET/CT have a high sensitivity in detecting lesions of prostate cancer with a high tumor to background contrast, even at low-serum PSA levels.[5] Brain, liver, and penis are some of the organs which are uncommonly involved in carcinoma of the prostate. There are very few case reports till date which revealed detection of these sites on Ga-68 PSMA PET/CT. A case series' described three unusual sites of metastases (brain, penis, and liver) from prostate cancer.[67] Our case describes the first case of Ga-068 PSMA PET/CT detecting penile metastasis with priapism in the initial staging of prostate cancer. Regardless of mechanism of spread or site of primary cancer, the prognosis of secondary penile malignancies is generally poor. It is reported that the average survival of such patients is approximately 9 months, with an overall survival of <18 months. Treatment of secondary penile lesions with malignant priapism has generally been aimed at palliation and improved quality of life, including surgical management of priapism and a possibility of penectomy for cutaneous lesions, urinary symptoms, and pain.[8] In conclusion, metastatic prostatic cancer presents with various signs and symptoms, and one should keep in mind the possibility of the penis as the site for metastasis. Ga-68 PSMA PET/CT scan allows detection of the metastatic sites, even the rare sites making it a powerful diagnostic tool for an assessment of the extent of disease in patients of prostate cancer.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  8 in total

1.  Penile metastases from prostate cancer.

Authors:  Vinayak Rohan; Abhinandan Hanji; Jayesh Patel; Jignesh Goswami; Rajen Tankshali
Journal:  Urol J       Date:  2009       Impact factor: 1.510

Review 2.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 3.  Metastatic tumors to the penis: a report of 17 cases and review of the literature.

Authors:  Alcides Chaux; Mahul Amin; Antonio L Cubilla; Robert H Young
Journal:  Int J Surg Pathol       Date:  2010-01-14       Impact factor: 1.271

4.  Malignant priapism due to penile metastases: Case series and literature review.

Authors:  Francesco De Luca; Evangelos Zacharakis; Majed Shabbir; Angela Maurizi; Emy Manzi; Antonio Zanghì; Carlo De Dominicis; David Ralph
Journal:  Arch Ital Urol Androl       Date:  2016-07-04

5.  Penile metastasis of prostatic adenocarcinoma: Report of two cases and review of literature.

Authors:  Joe Philip; Joseph Mathew
Journal:  World J Surg Oncol       Date:  2003-09-14       Impact factor: 2.754

6.  The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-20       Impact factor: 9.236

7.  Specificity of 68Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality.

Authors:  Arun Sasikumar
Journal:  Indian J Nucl Med       Date:  2017 Jan-Mar

8.  Rare Sites of Metastases in Prostate Cancer Detected on Ga-68 PSMA PET/CT Scan-A Case Series.

Authors:  Sugandha Dureja; Parul Thakral; Vineet Pant; Ishita Sen
Journal:  Indian J Nucl Med       Date:  2017 Jan-Mar
  8 in total
  3 in total

1.  Case Report: 18F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer.

Authors:  Junjie Fan; Hua Liang; Xing Zhang; Xingfa Chen; Xiaoyi Duan; Lei Li; Dalin He; Kaijie Wu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

2.  Patient with penile metastasis from prostate cancer and survival over 5 years: A case report with longitudinal evaluation using computed tomography and magnetic resonance imaging.

Authors:  Nana Fujita; Ryo Kurokawa; Risa Kaneshima; Munetaka Machida; Go Kawai; Tomoki Wada; Masamichi Takahashi; Moto Nakaya; Naoya Sakamoto; Shinichi Cho; Osamu Abe; Yujiro Matsuoka
Journal:  Radiol Case Rep       Date:  2021-03-26

3.  Penile secondary lesions: a rare entity detected by PET/CT.

Authors:  Tima Davidson; Liran Domachevsky; Yogev Giladi; Eddie Fridman; Zohar Dotan; Barak Rosenzweig; Raya Leibowitz; Jennifer Ben Shimol
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.